CNBC Exclusive: CNBC Transcript: Pfizer Inc. (NYSE:PFE) Chairman and CEO Albert Bourla Speaks with CNBC’s “The Exchange” Today Q1 2021 hedge fund letters, conferences and more...
Next year, people are likely to need an annual Covid-19 vaccination just like they need an annual flu shot. That prediction is made by researchers at...
Europe’s regulator has begun a rolling review of Sinovac’s COVID-19 vaccine, known as Vero Cell. The vaccine is The post EU starts rolling review of Sinovac’s...
An experimental monoclonal antibody treatment for Covid-19 being developed by Eli Lilly and Co. and AbCellera Biologics Inc. can "potently" neutralize numerous coronavirus variants, including those first...
In this eBook, sponsored by Sartorius, we highlight the research efforts and related applications utilized to study binding affinity, potency and target specificities of neutralizing antibodies...
The CDC first paused, then unpaused, the administration of the Johnson & Johnson COVID-19 vaccine due to concerns about blood clots. But what are those clots,...
Penny stocks are back and better than ever; should you watch these 3 in May? The post 3 Penny Stocks With Huge Potential in May 2021...
Adeno-associated virus (AAV) vectors are the leading vectors for gene delivery. AAV vectors pose challenges including costly manufacture, high percentages of empty capsids, and safety issues...
CloseCloseCloseHealthcare has been lagging the market, but that is now changing.As biotechs consolidate, other healthcare industry groups are powering the sector to a breakout.Medical Devices and...
A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already...
The developments are coming in thick and fast at Sorrento Therapeutics (SRNE). Recent times have seen a flurry of announcements regrading the company’s bulging pipeline. Earlier...
The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co.'s rheumatoid arthritis drug Olumiant for hospitalized Covid-19 patients getting oxygen, the EU...
Leaked documents from provincial and municipal governments in China reveal a slew of previously unreported severe adverse events related to Covid-19 vaccines made and administered in...
A DNA vaccine candidate for MERS-CoV induced potent immune responses and afforded protective efficacy in non-human primate models when given intradermally in a low-dose immunization regimen....
As a massive Covid-19 surge continues to rage on throughout India, scientists and public health officials scramble to determine whether currently authorized vaccines in the country...
The CDC and FDA said the benefits of the Johnson & Johnson vaccine far outweigh the low risk of developing rare blood clots and lifted a...
Enrollment begins at NIH Clinical Center Credit: NIAID A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling...
The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford Covid-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated...
The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, The post FDA approves under-pressure GSK’s Jemperli for...
From asymptomatic SARS-CoV-2 carriers to hospitalized COVID-19 patients, little is known about the relationship between the severity of disease and the extent of the immune response....
Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild...
Swiss drugmaker Roche predicted on April 21 that demand for the company's drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests...
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which The post EMA starts review of GSK/Vir COVID-19...
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last The post Clive Dix: Rebuilding UK biotech appeared...
Dominant G-form Spike protein ‘puts its head up’ more frequently to latch on to receptors, but that makes it more vulnerable to neutralization Credit: Los Alamos...
Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the...
Is more testing really the best way to achieve our aim of living safely with COVID-19?
Variants of the original SARS-CoV-2 are now in wide circulation. That means the third wave of COVID-19 has come with new questions about the variants, their...